Myriad Genetics, Inc. (MYGN): Price and Financial Metrics


Myriad Genetics, Inc. (MYGN): $21.17

-0.09 (-0.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MYGN POWR Grades


  • Value is the dimension where MYGN ranks best; there it ranks ahead of 83.84% of US stocks.
  • The strongest trend for MYGN is in Growth, which has been heading up over the past 179 days.
  • MYGN ranks lowest in Momentum; there it ranks in the 5th percentile.

MYGN Stock Summary

  • Price to trailing twelve month operating cash flow for MYGN is currently 114.71, higher than 96.18% of US stocks with positive operating cash flow.
  • For MYGN, its debt to operating expenses ratio is greater than that reported by merely 16.49% of US equities we're observing.
  • With a year-over-year growth in debt of -68.06%, Myriad Genetics Inc's debt growth rate surpasses only 4.28% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Myriad Genetics Inc, a group of peers worth examining would be MYO, ITI, LPTH, AGRX, and RFIL.
  • Visit MYGN's SEC page to see the company's official filings. To visit the company's web site, go to myriad.com.

MYGN Valuation Summary

  • MYGN's price/sales ratio is 4.2; this is 10.53% higher than that of the median Healthcare stock.
  • MYGN's price/sales ratio has moved down 18.4 over the prior 243 months.
  • Over the past 243 months, MYGN's price/earnings ratio has gone up 101.3.

Below are key valuation metrics over time for MYGN.

Stock Date P/S P/B P/E EV/EBIT
MYGN 2021-08-31 4.2 3.1 -28.7 -21.0
MYGN 2021-08-30 4.2 3.1 -28.7 -21.1
MYGN 2021-08-27 4.2 3.1 -28.3 -20.8
MYGN 2021-08-26 4.0 2.9 -26.9 -19.8
MYGN 2021-08-25 4.1 3.0 -27.9 -20.5
MYGN 2021-08-24 4.1 3.0 -28.2 -20.6

MYGN Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 0.41%.
  • Its year over year cash and equivalents growth rate is now at 23.06%.
  • Its 2 year cash and equivalents growth rate is now at 24.23%.
MYGN's revenue has moved down $140,000,000 over the prior 34 months.

The table below shows MYGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 690.6 18.2 -27.2
2021-09-30 684.4 13.7 -57.5
2021-06-30 662.3 -6.3 -97.3
2021-03-31 566.1 28.1 -148
2020-12-31 557 -26.9 -223.7
2020-09-30 597.5 -14.4 -194.1

MYGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MYGN has a Quality Grade of C, ranking ahead of 61.95% of graded US stocks.
  • MYGN's asset turnover comes in at 0.476 -- ranking 93rd of 681 Pharmaceutical Products stocks.
  • CDXC, CEMI, and GERN are the stocks whose asset turnover ratios are most correlated with MYGN.

The table below shows MYGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.476 0.705 -0.277
2021-03-31 0.404 0.685 -0.395
2020-12-31 0.390 0.680 -0.514
2020-09-30 0.407 0.698 -0.425
2020-06-30 0.424 0.709 -0.380
2020-03-31 0.493 0.737 -0.285

MYGN Price Target

For more insight on analysts targets of MYGN, see our MYGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.25 Average Broker Recommendation 2.11 (Hold)

MYGN Stock Price Chart Interactive Chart >

Price chart for MYGN

MYGN Price/Volume Stats

Current price $21.17 52-week high $36.95
Prev. close $21.26 52-week low $18.98
Day low $20.86 Volume 192,306
Day high $22.18 Avg. volume 534,529
50-day MA $22.95 Dividend yield N/A
200-day MA $27.48 Market Cap 1.70B

Myriad Genetics, Inc. (MYGN) Company Bio


Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.


MYGN Latest News Stream


Event/Time News Detail
Loading, please wait...

MYGN Latest Social Stream


Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about Myriad Genetics Inc that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Myriad Genetics, Inc. (MYGN) CEO Paul Diaz on Q4 2021 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q4 2021 Earnings Conference Call February 24, 2022 16:30 ET Company Participants Nathan Smith - Senior Vice President of Investor Relations & Treasury Paul Diaz - President & Chief Executive Officer Nicole Lambert - Chief Operating Officer Bryan Riggsbee - Executive Vice President & Chief Financial...

SA Transcripts on Seeking Alpha | February 25, 2022

Myriad Genetics (MYGN) Reports Q4 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives

Highlights: Strong business performance despite COVID-19 headwindsRevenue of $160.8 million in the fourth quarter and $690.6 million for the year ended Dec. 31, 2021, up 4% and 24%, respectively Excluding revenue from divested businesses, revenue increased 19% for the fourth quarter and 34% for the year Diluted GAAP earnings per share (EPS) of $(0.10) and adjusted EPS of $(0.02) in the fourth quarter of 2021Ended the quarter with $398.8 million in cash, cash equivalents and investments SALT LAKE

Yahoo | February 24, 2022

New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test

Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorderSALT LAKE CITY, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis of GeneSight® Psychotropic, the company’s mental health medication test, in its Feb. 2022 edition. The study sh

Yahoo | February 23, 2022

Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 1.64% and 11.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 17, 2022

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo 0.14%
3-mo -14.26%
6-mo -20.44%
1-year -26.03%
3-year -13.56%
5-year 4.23%
YTD -23.30%
2021 39.57%
2020 -27.38%
2019 -6.33%
2018 -15.36%
2017 106.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9203 seconds.